



## Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

February 19, 2025

WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen's 45<sup>th</sup> Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at <https://ir.ardelyx.com/events-and-presentations>. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

### About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA<sup>®</sup> (tenapanor) and XPHOZAH<sup>®</sup> (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL<sup>®</sup> (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit <https://ardelyx.com/> and connect with us on [X \(formerly known as Twitter\)](#), [LinkedIn](#) and [Facebook](#).

### Investor and Media Contacts:

Caitlin Lowie

[clowie@ardelyx.com](mailto:clowie@ardelyx.com)



Source: Ardelyx, Inc.